MedTrace Logo

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

NCT02507570 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-03-19

No results posted yet for this study

Summary

This is an open label study designed to examine the effects of Enzalutamide with concurrent administration of Radium Ra 223 dichloride in Castrate-Resistant (Hormone-Refractory) Prostate Cancer subjects with symptomatic bone metastases in both the pre- and post-chemotherapy setting.

Conditions

  • Prostate Carcinoma Metastatic to the Bone

Interventions

DRUG

Enzalutamide

used concomitantly

RADIATION

Radium ra 223 dichloride

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Carolina Research Professionals, LLC

    lead OTHER

Principal Investigators

  • Neal D Shore, MD · Carolina Research Professionals, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-23
Primary Completion
2019-01-18
Completion
2019-01-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02507570 on ClinicalTrials.gov